A persistent gap remains between what Annex 1 requires and what facilities can demonstrate. Let's take a closer look at four common compliance failures.
- Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- Affinity Membranes Are Moving Closer To Commercial Reality
- AI Has Arrived In Biotech CMC Amid Patchwork Governance
- Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
- The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
- CDMO Selection: Start With The Relationship, Not The RFP
GUEST COLUMNISTS
-
Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
Are you ready? FDA has begun to implement the use of artificial intelligence in its operations, particularly during inspection activities.
-
A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.
-
Affinity Membranes Are Moving Closer To Commercial Reality
A recent review shows advances in surface chemistry and ligand engineering are moving the needle for next-generation affinity membranes.
-
AI Has Arrived In Biotech CMC Amid Patchwork Governance
AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.
-
Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models
Let's delve into the key pitfalls to avoid when working with a CDMO and the integrated execution model that solves or mitigates these pitfalls before they occur.
-
The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process
Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.
-
CDMO Selection: Start With The Relationship, Not The RFP
Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.
BIOSIMILAR WHITE PAPERS
-
Why Biopharma Breakthroughs Aren't Moving The Market
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators4/28/2025
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Perfusion Cell Line Development For Intensified Processes5/5/2025
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
How Lipid Nanoparticles Enable Next-Gen Delivery10/20/2025
Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.
-
2024 Global Biopharma Sustainability Review9/3/2024
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Organon Canada And Henlius Expand Access To Denosumab Treatments With Launch Of BILDYOS (denosumab injection) And TUZEMTY (denosumab injection), Biosimilars To PROLIA And XGEVA
- Organon And Samsung Bioepis Expand Agreement To Commercialize PYZCHIVA (ustekinumab), A Biosimilar Referencing STELARA (ustekinumab) In Canada
- AAM Applauds Momentum As Two Bills Move Through Senate HELP Committee
- Sandoz Steps Up In-House Biosimilar Capabilities, Opening State-Of-The-Art Development Centre To Capture 'Golden Decade' Opportunity
- Alvotech Announces FDA Acceptance Of Biologics License Application For AVT16, A Proposed Interchangeable Biosimilar To Entyvio®
- Xbrane Biopharma AB And JOINN Biologics US Inc. Enter Strategic Partnership To Develop Xdarzane – Xbrane´s Biosimilar Candidate To Darzalex (Daratumumab)
- Abbott Receives Approval For Two New Biosimilars In Brazil, Expanding Access To Treatment For Osteoporosis And Bone Complications Related To Cancer
- Organon Secures US Food And Drug Administration Approval Expanding Indications For TOFIDENCE (tocilizumab-bavi) In Cytokine Release Syndrome (CRS) And Pediatric COVID-19
NEWSLETTER ARCHIVE
- 06.25.26 -- Smarter risk management for single-use and filtration systems.
- 06.25.26 -- What To Do About Process Drift In Your Biosimilar's Reference Product
- 06.18.26 -- Reduce mAb Aggregates: Practical Strategies
- 06.18.26 -- Will FDA's One-Day Inspection Pilot Stand The Test Of Time?
- 06.11.26 -- Process Intensification: Your Guide To "Doing More With Less"